Guangzhou Mingkang Bioengineering

Guangzhou Mingkang Bioengineering is a Chinese biopharmaceutical company dedicated to the research, development, and large-scale production of recombinant protein and peptide therapeutics. The company focuses primarily on metabolic disorders, with a robust portfolio of insulin analogs and GLP-1 receptor agonists designed to treat diabetes and obesity. Mingkang Bioengineering operates advanced manufacturing facilities that comply with international standards, enabling the production of high-quality biosimilars and innovative biologics. By leveraging its expertise in protein expression and purification, the company aims to provide affordable and effective treatment options for patients with chronic endocrine diseases.